Discovery Cut · 1:44 · English
Peptides in 2TM · Sermorelin
Sermorelin | The 29 Amino Acids That Put GHRH to Work
One height measurement captures a moment. A series of measurements shows how fast a child is growing. When growth slows, clinicians may investigate whether the pituitary can release enough growth hormone. Sermorelin gave them a way to ask the gland to respond. [1–2]
Sermorelin reproduces the first 29 amino acids of human growth hormone–releasing hormone (GHRH) in an amidated form known as GHRH(1–29)-amide. The fragment retains the ability to stimulate growth hormone release from the pituitary. This Discovery Cut follows that signal from the brain to the clinic, where two formulations of Geref served different purposes. [1–2]
English narration with optional English captions.
Inside the film
Select a time to play from that point.
- What a child’s height can tell us
- The brain signal that prompts growth hormone release
- Sermorelin and the first 29 amino acids
- Geref in 1990 and the pituitary response
- Geref in 1997 and childhood growth
- What remains after Geref
What the test and the treatment studies measured
Evaluating the pituitary’s response
On December 28, 1990, the FDA approved a Geref formulation for evaluating the ability of the pituitary’s growth hormone–producing cells to release the hormone. Measuring growth hormone in blood after stimulation captured how the gland responded during the test. [2]
Following growth over time
On September 26, 1997, the FDA approved a separate formulation for children with growth failure due to growth hormone deficiency of unknown cause. In a 1996 report, Michael Thorner and the Geref International Study Group found an increase in first-year growth velocity in children studied with GHRH(1–29). Growth velocity is the rate at which height changes over time. The study addressed growth in the children enrolled during the first year. [2–3]
What happened to Geref
The manufacturer discontinued the original Geref products, and the FDA withdrew the two approvals effective June 18, 2009, at the manufacturer’s request. In 2013, the FDA reviewed the reason for discontinuation and found that neither product had been withdrawn from sale for safety or effectiveness reasons. That finding concerned the original Geref products. The two historical approvals applied to their specific formulations and indications. [2]
Related films
Tesamorelin follows another peptide designed from the GHRH signal into a different clinical setting. Watch Tesamorelin
CJC‑1295 follows the development of a longer-acting GHRH analog and examines what the early human studies measured. Watch CJC‑1295
Ipamorelin explores how a peptide can stimulate growth hormone release through the ghrelin receptor. Watch Ipamorelin
The complete English transcript
A child’s height is recorded at a clinic.
One measurement tells you how tall they are.
A series of measurements tells you how fast they’re growing.
When growth slows, one question
is whether the pituitary can release enough growth hormone.
Our last film followed that signal back to the brain.
It’s called growth hormone–releasing hormone, or GHRH.
The next discovery was how much
of that signal could fit into a shorter peptide.
Sermorelin is the active first 29 amino acids
of human GHRH.
It stimulates the pituitary to release its own growth hormone.
That gave clinicians a way to ask a specific question.
How much growth hormone can the gland release when prompted?
In 1990, the FDA approved a formulation
called Geref for evaluating that response.
Clinicians measured growth hormone in blood after giving the signal.
The test looked at the pituitary’s response in the moment.
Seven years later, a separate Geref formulation
was approved for certain children with growth failure
due to growth hormone deficiency of unknown cause.
In treatment studies, researchers
followed how fast the children grew over time.
The original Geref products were later discontinued.
They left behind a lesson in hormone signaling.
Twenty-nine amino acids carried enough of the brain’s message
to make the pituitary respond.
Peptides in 2.
World Peptide Foundation.
Every experience matters.
Original sources & further reading
- [1] U.S. National Library of Medicine. Sermorelin. Medical Subject Headings, D017337.
- [2] U.S. Food and Drug Administration. Geref determination. Federal Register. March 4, 2013.
- [3] Thorner MO et al., Geref International Study Group. Journal of Clinical Endocrinology & Metabolism. 1996;81(3):1189–1196. PMID 8772599.
Synthetic-content disclosure
The film uses AI-generated clinical and laboratory reconstructions, original music, and synthetic Tom narration.